Otsuka Holdings Co., Ltd.: Leukemia trials

The registry lists 21 Leukemia studies with Otsuka Holdings Co., Ltd. as lead sponsor. 1 are open to participants now and 9 have results posted.

Phase 1 10Phase 2 6Phase 3 6No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)RecruitingNCT04256317Phase 2/3
• Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AMLCompletedNCT03306264Phase 3Results posted
• Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid LeukemiaCompletedNCT02920008Phase 3Results posted
• Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAsCompletedNCT02907359Phase 3Results posted
• SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission InductionCompletedNCT02348489Phase 3Results posted
• Phase 1 Study of SGI-110 in Patients With Acute Myeloid LeukemiaCompletedNCT02293993Phase 1Results posted
• A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid LeukemiaCompletedNCT01961882Phase 2Results posted
• Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)CompletedNCT01475370Phase 1Results posted
• A Phase I Study of OCV-501 in Acute Myeloid Leukemia PatientsCompletedNCT01440920Phase 1Results posted
• Phase I Study of OPB-51602 in Patients With Hematologic MalignanciesCompletedNCT01344876Phase 1Results posted
• A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT05883956Phase 3
• A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid NeoplasmsTerminatedNCT04637009Phase 1
• A Study of TAS1440 With ATRA in Subjects With r/r AMLTerminatedNCT04282668Phase 1
• A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)TerminatedNCT04155580Phase 1
• Effect of Food on Blood Levels of ASTX727CompletedNCT03813186Phase 1
• Iclusig PMS in CML or Ph+ALL PatientsStatus unknownNCT03709017
• Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory LeukemiasWithdrawnNCT01239108Phase 1
• Study to Assess the Safety of Escalating Doses of AT9283, in Patients With LeukemiasTerminatedNCT00522990Phase 1/2
• Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)CompletedNCT00042016Phase 2
• Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)CompletedNCT00042003Phase 2
• Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)CompletedNCT00041990Phase 2